Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 5, 2013, Pages 494-502

  Endo, Kei ^a   Saiki, Atsuhito ^a   Yamaguchi, Takashi ^a   Sakuma, Kiyoshi ^a   Sasaki, Hidehisa ^b   Ban, Noriko ^a   Kawana, Hidetoshi ^a   Nagayama, Daiji ^a   Nagumo, Ayako ^a   Ohira, Masahiro ^a   Oyama, Tomokazu ^a   Murano, Takeyoshi ^a   Miyashita, Yoh ^a   Yamamura, Shigeo ^c   Suzuki, Yasuo ^a   Shirai, Kohji ^a   Tatsuno, Ichiro ^a  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c Josai Internal University Pharmaceutical Sciences   (Japan)

Author keywords

Anti oxidant effect; Chronic kidney disease; Diabetic nephropathy; Hemodialysis; Probucol

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PROBUCOL; SULFONYLUREA;

ADULT; ARTICLE; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEATH; DIABETIC NEPHROPATHY; DISEASE COURSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; UREMIA;

AGED; ALBUMINURIA; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; JAPAN; KIDNEY; MALE; MIDDLE AGED; PROBUCOL; RENAL DIALYSIS;

EID: 84878413028     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.15263     Document Type: Article

References (38)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of Angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med, 1993; 329: 1456-1462
2. Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T, Matsuo S, Hotta N, Sakamoto N: Effects of long-term enalapril treatment on persistent microalbuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care, 1994; 17: 420-424
3. Sano T, Hotta N, Kawamura T, Matsumae H, Chaya S, Sasaki H, Nakayama M, Hara T, Matsuo S, Sakamoto N: Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients; results of a 4-year, prospective, randomized study. Diabetic Medicine, 1996; 13: 120-124
4. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients. Ann Intern Med, 1993; 118: 577-581
5. Agardh CD, Garcia-Puig J, Charbonnel B, Angerkort B, Barnett AH: Greater reduction of urinary albumin excretion in hypertensive type 2 diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens, 1996; 10: 185-192
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001; 345: 851-860
7. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001; 345: 861-869
8. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 2001; 345: 870-878
9. Baynes JW: Role of oxidative stress in development of complication in diabetes. Diabetes, 1991; 40: 405-412
10. Lyons TJ: Oxidized LDL: a role in the pathogenesis of atherosclerosis in diabetes? Diabetic Med, 1991; 8: 411-419
11. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. Diabetes Care, 1996; 19: 257-267
12. Baynes JW, Thorpe SR: The role of oxidative stress in diabetic complications. Curr Opin Endocrinol, 1997; 3: 277-284
13. Van Dam PS, Van Asbeck BS, Erkelens BW, Marx JJM, Gispen W-H, Bravenboer B: The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev, 1995; 11: 181-192
14. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications. Diabetes Care, 1999; 48: 1-9
15. Kedziora-Kornatowska KZ, Luciak M, Blaszczyk J, Pawlak W: Lipid peroxidation and activities of antioxidant enzymes in erythrocytes of patients with non-insulin dependent diabetes with or without nephropathy. Nephrol Dial Transplant, 1998; 13: 2829-2832
16. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Narumiya S, Kawai C: Prevention of atherosclerotic progression in Watanabe rabbits by probucol. Am J Cardiol, 1988; 62: 13B-19B
17. Chisolm GM, Morel DW: Lipoprotein oxidation and cytotoxicity: Effect of probucol on streptozotocin-treatment rats. Am J Cardiol, 1988; 62: 20B-26
18. Morel DW, Chisolm GM: Antioxidant treatment of diabetic rat inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res, 1989; 30: 1827-1834
19. Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D: Probucol prevents oxidative modification of low-density lipoprotein. J Clin Invest, 1986; 77: 641
20. Endo K, Miyashita Y, Ebisuno M, Ohira M, Saiki A, Koide N, Oyama T, Murano T, Shirai K: Probucol and atorvastatin decreased urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. J Atheroscler Thromb, 2006; 13: 68-75
21. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M; Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol, 2003; 14: S250-S253
22. Endo K, Miyashita Y, Sasaki H, Ohira M, Saiki A, Koide N, Otsuka M, Oyama T, Murano T, Ito Y, Shirai K: Probucol delays progression of diabetic nephropathy. Diabetes Res Clin Prac, 2006; 71: 156-163
23. Research guidelines for initiation of hemodialysis. Research by the Ministry of Welfare in Japan 1991. The report of medical research on renal dysfunction. 1992; 125-132
24. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of disbetes mellitus. J Jpn Diabetes Soc, 2010; 53: 450-467
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc, 1958; 53: 457-481
26. Nishimura M, Sasaki T, Ohishi A, Kono Y, Totani Y, Kato Y, Noto Y, Misaki S, Higashi K, Shimada F, Wakasugi H, Inoue K, Hoshiyama Y, Yamada K: Angiotensin-converting enzyme inhibitors and probucol suppress the timedependent increase in urinary Type IV collagen excretion of Type 2 diabetes mellitus patients with early diabetic nephropathy. Clinical Nephrology, 2001; 56: 96-103
27. Abe M, Maruyama N, Yoshida Y, Ito M, Okada K, Soma M: Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. Endocrine J, 2011; 58: 663-674
28. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators: Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis, 2009; 54: 810-819
29. Ban N, Saiki A, Endo K, Murano T, Tatsuno I: Protective effect of probucol against oxidative cell damage induced by oxidized LDL and high glucose in human mesangial cells. Journal of the Medical Society of Toho University, 2012; 59: 123-132
30. McPherson R, Hogue M, Milne RW, Tall AR, Marcel YL: Increase in plasma cholesterol ester transfer protein during in high-density lipoprotein composition. Arterioscler Thromb Vasc Biol, 1991; 11: 476-481
31. Franceschini G, Werba JP, Carabresi L: Drug control of reverse cholesterol transport. Pharmacol Ther, 1994; 61: 289-324
32. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J: Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hyperlipidemia. J Am Coll Cardiol, 2002; 39: 610-616
33. Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H, Nakata Y, Kutsumi Y, Oshima S: Effectiveness of an anti-oxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The probucol angioplasty restenosis trial. J Am Coll Cardiol, 1997; 30: 855-862
34. Yamashita S, Bujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y: Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2008; 15: 292-303
35. Moorhead JF, Chan MK, El-Nahas M, Valghes Z: Lipid nephrotoxicity in chronic progressive glomerular and tubule-interstitial disease. Lancet, 1982; ii: 1309-1312
36. Kean WF, Kasiske BL, O'Donnell MP: Lipid and progressive glomerulosclerosis: A model analogous to atherosclerosis. Am J Nephrol, 1988; 8: 261-271
37. Wasserman J, Santiago A, Rifici V, Holthofer H, Scharchmidt L, Epstein M, Schlondorff D: Interactions of low density lipoprotein with rat mesangial cells. Kidney Int, 1989; 35: 1168-1174
38. Grone FE, Abboud HE, Hohne M, Walli AK, Grone HJ, Stuker D, Robenek H, Wieland E, Seidel D: Action of lipoproteins in cultured human mesangial cells: Modulation by mitogenic vasoconstrictors, Am J Physiol, 1992; 263: F686-696